advances immunocytochemistry electron microscopy cell culture molecular techniques demonstrated NUMBER NUMBER clinically nonfunctioning pituitary adenomas recently recognized gonadotropinomas account NUMBER NUMBER pituitary macroadenomas patients usually present mass effects including visual field loss headache hypogonadism hypopituitarism commonly tumor incidentally recently patients gonadotropinomas reported hormonal hypersecretion syndromes ovarian hyperstimulation testicular enlargement precocious puberty tumors divided broad categories functioning gonadotropinomas positive immunostaining hormone leutinizing hormone subunits nonfunctioning gonadotropinomas null cell tumors negative immunostaining pituitary hormones positive nuclear immunostaining steroid characteristic gonadotrope differentiation evidence gonadotropin production gene expression mrna level gonadotropinomas monoclonal origin pathogenesis tumors unknown factors stimulate clonal proliferation determined new pituitary oncogene pituitary tumor transforming gene recently overexpressed thirds tumors detected pituitary tumor subtypes alterations tumor hormone receptors local growth factors play role tumor development progression transphenoidal surgery remains principal therapy macroadenomas radiosurgery using gamma knife linear accelerator proton beam therapy showed promising results especially controlling residual recurrent tumors medical therapy somatostatin analogs dopamine agonists hormone agonists antagonists rarely effective reducing tumor size experimental therapy intraoperative local chemotherapy potential gene therapy requires investigation references NUMBER gonadotrope derived follicle stimulating factor NUMBER dax NUMBER gonadotropin releasing